▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Korea’s botulinum toxin maker Medytox said on Aug. 23 it has opened a research center to push its drug development beyond facial injectables. The Medytox Research & Development Cente...
[THE INVESTOR] Korea’s Dong-A ST said on Aug. 23 it has reached a technology transfer agreement for its four therapies with Iran’s pharmaceutical firm Rooyan Darou, seeking to gain access to the pot...
[THE INVESTOR] Celltrion could attract 300 billion won (US$264 million) of fresh investment if it shifts from secondary bourse KOSDAQ to the benchmark KOSPI, a local securities firm said on Aug. 22...
[THE INVESTOR] Korea’s biosimilar maker Celltrion has denied a news report that its proposed biosimilar of Herceptin could face delayed European approval due to late data submission. The European M...
[THE INVESTOR] Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, said on Aug. 21 that it has signed an agreement with Japan’s largest drug maker Takeda Pharmaceutical to jointly...
[THE INVESTOR] Celltrion has decided to convene an extraordinary general meeting on Sept. 29 to discuss its possible relisting on the nation’s benchmark KOSPI. The meeting comes after some minority...
[THE INVESTOR] Korean biotech firm Samsung Bioepis is expected to take the lead in the race to get a copycat version of Roche’s Herceptin to market in Europe, as India’s Biocon withdrew its filing. ...
[THE INVESTOR] Korean biotech company SillaJen said Aug. 17 it had signed a contract with the National Cancer Institute, a medical research agency of the US government, for the development of a comb...
[THE INVESTOR] Celltrion , a Korean biosimilar drugmaker, said Aug. 17 it will hold an extraordinary general meeting before the end of September to decide whether the largest stock on the secondary...
[THE INVESTOR] Korean drug makers on Aug. 17 ruled out the possibility that they had used tainted eggs in their flu vaccines amid growing health concerns after the government found some eggs contami...
[THE INVESTOR] Korean drug makers are poised to challenge Gilead Sciences with their own versions of the US firm’s blockbuster treatment Viread here, industry sources said on Aug. 16. As the Minist...
[THE INVESTOR] Korean botulinum toxin maker Medytox recorded record-high earnings for a tenth quarter in a row. The biotech firm said on Aug.14 that it logged a net income of 20.5 billion won (US$1...
[ THE INVESTOR ] Korean biotech firm Huons said on Aug. 14 that its anti-wrinkle treatment Hutox saw sales jump 58.1 percent on-quarter during the period of April to June this year. Riding on th...
[THE INVESTOR] US biopharmaceutical company Biogen has officially established a new South Korean branch to take charge of the firm’s business here, according to news reports Sunday. Biogen Korea LL...
[THE INVESTOR] SK Biopharmaceuticals’ US$10 million-plus license-out deal with US Acorda Therapeutics is on the verge of collapsing as the Korean firm’s investigational epilepsy drug Plumiaz has fai...
SK hynix may be far from acquiring Toshiba
LG to build EV-parts factory in US
SK Planet mulls exit from Indonesia
Korean mobile games still shut out of China
Hyundai Santa Cruz gets green light for production
Celltrion could attract W300b with KOSPI relisting
FTC chief urges Hyundai to tackle governance structure
Samsung Galaxy Note 8 ditches ATL batteries
